RT Journal Article
T1 Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition.
A1 Turner, Dan
A1 Ruemmele, Frank M
A1 Orlanski-Meyer, Esther
A1 Griffiths, Anne M
A1 de Carpi, Javier Martin
A1 Bronsky, Jiri
A1 Veres, Gabor
A1 Aloi, Marina
A1 Strisciuglio, Caterina
A1 Braegger, Christian P
A1 Assa, Amit
A1 Romano, Claudio
A1 Hussey, Séamus
A1 Stanton, Michael
A1 Pakarinen, Mikko
A1 de Ridder, Lissy
A1 Katsanos, Konstantinos
A1 Croft, Nick
A1 Navas-López, Victor
A1 Wilson, David C
A1 Lawrence, Sally
A1 Russell, Richard K
K1 Acute severe colitis
K1 Antibiotics
K1 Anti-coagulants
K1 Anti-TNF
K1 Colectomy
K1 Mesalamine
K1 Pediatric Ulcerative Colitis Activity Index
K1 Prediction
K1 Steroids
AB The contemporary management of ambulatory ulcerative colitis (UC) continues to be challenging with ∼20% of children needing a colectomy within childhood years. We thus aimed to standardize daily treatment of pediatric UC and inflammatory bowel diseases (IBD)-unclassified through detailed recommendations and practice points. These guidelines are a joint effort of the European Crohn's and Colitis Organization (ECCO) and the Paediatric IBD Porto group of European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). An extensive literature search with subsequent evidence appraisal using robust methodology was performed before 2 face-to-face meetings. All 40 included recommendations and 86 practice points were endorsed by 43 experts in Paediatric IBD with at least an 88% consensus rate. These guidelines discuss how to optimize the use of mesalamine (including topical), systemic and locally active steroids, thiopurines and, for more severe disease, biologics. The use of other emerging therapies and the role of surgery are also covered. Algorithms are provided to aid therapeutic decision-making based on clinical assessment and the Paediatric UC Activity Index (PUCAI). Advice on contemporary therapeutic targets incorporating the use of calprotectin and the role of therapeutic drug monitoring are presented, as well as other management considerations around pouchitis, extraintestinal manifestations, nutrition, growth, psychology, and transition. A brief section on disease classification using the PIBD-classes criteria and IBD-unclassified is also part of these guidelines. These guidelines provide a guide to clinicians managing children with UC and IBD-unclassified management to provide modern management strategies while maintaining vigilance around appropriate outcomes and safety issues.
YR 2018
FD 2018
LK http://hdl.handle.net/10668/12752
UL http://hdl.handle.net/10668/12752
LA en
DS RISalud
RD Apr 18, 2025